Two AI‑focused biotech financings closed this week as investors back algorithmic protein and immunology discovery. Seoul‑based Galux raised $29 million in a Series B to scale its AI‑driven biologics platform and protein design pipeline. China‑American QuantX secured an $85 million Series B led by Lilly and Sanofi Ventures to advance a pipeline targeting popular immunology pathways. Both rounds signal sustained investor appetite for AI‑enabled R&D tools and early therapeutic assets that can be rapidly iterated.